Brought to you by 
Series B leads to $15.3mm for Axial Biotech
29 Mar 2007
Executive Summary
Axial Biotech (diagnostics and devices for spinal disorders) raised $15.3mm in its two-tranche Series B financing led by first-time backer Johnson & Johnson Development Corp., which was joined by returning shareholders vSpring Capital and Ohio Biotech Group. The company will use the money for ongoing development and eventual launch of its scoliosis genetic test. A member of J&J Development takes a seat on Axial's board.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B leads to $15.3mm for Axial Biotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice